Michelle E A Borm
Roche (Switzerland)(CH)
Publications by Year
Research Areas
Rheumatoid Arthritis Research and Therapies, Chronic Lymphocytic Leukemia Research, Inflammatory Bowel Disease, Bioinformatics and Genomic Networks, Systemic Lupus Erythematosus Research
Most-Cited Works
- → Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial(2016)245 cited
- → Evaluation of the International Study Group of Pancreatic Surgery definition of delayed gastric emptying after pancreatoduodenectomy in a high-volume centre(2010)150 cited
- → A NFKB1 promoter polymorphism is involved in susceptibility to ulcerative colitis(2005)90 cited
- → Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors(2018)51 cited
- → A major quantitative trait locus on mouse chromosome 3 is involved in disease susceptibility in different colitis models(2005)46 cited
- → The effect of NOD2 activation on TLR2-mediated cytokine responses is dependent on activation dose and NOD2 genotype(2008)45 cited
- → Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology(2018)36 cited
- → Severity of COVID-19 and adverse long-term outcomes: a retrospective cohort study based on a US electronic health record database(2021)35 cited
- → IL12B and IRF1 gene polymorphisms and susceptibility to celiac disease(2003)31 cited
- → Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials(2019)23 cited